Sibutramine and the sympathetic nervous system in obese humans

Clinical Autonomic Research

Volumn 15, Issue 3, 2005, Pages 189-192

  Haynes, William G ^a   Egri, Zoltan ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; HYDROCHLOROTHIAZIDE; METOPROLOL; NORADRENALIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TRANDOLAPRIL; VERAPAMIL;

ADRENERGIC SYSTEM; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HEART RATE; HUMAN; HYPERTENSION; META ANALYSIS; NONHUMAN; OBESITY; ORTHOSTATIC HYPOTENSION; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; BLOOD PRESSURE; CLINICAL TRIALS; CYCLOBUTANES; HEART RATE; HUMANS; HYPERTENSION; NOREPINEPHRINE; OBESITY; SEROTONIN UPTAKE INHIBITORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 21344439574     PISSN: 09599851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10286-005-0287-2     Document Type: Editorial

References (36)

1. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E (1999) Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106:179-184
2. Astrup A, Toubro S (2001) When, for whom and how to use sibutramine? Int J Obes 25(Suppl 4):S2-S7
3. Barkeling B, Elfhag K, Rooth P, Rössner S (2003) Short-term effects of sibutramine (Reductil™) on appetite and eating behaviour and the long-term therapeutic outcome. Int J Obes 27: 693-700
4. Bérubé-Parent S, Prud'homme D, St-Pierre S, Doucet E, Tremblay A (2001) Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention. Int J Obes 25:1144-1153
5. Birkenfeld AL, Schroeder C, Boschmann M, Tank Jens, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J (2002) Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106:2459-2465
6. Bray GA (2000) Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications. Int J Obes 24(Suppl 2): S9-S17
7. Ersoz HO, Ukinc K, Baykan M, Erem C, Durmus I, Hacihasanoglu A, Telatar M (2004) Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. Int J Obes 28:378-383
8. Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A (2000) A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes 24:144-150
9. Fernández MM, Calama E, Morán A, Martín ML, San Román L (2000) Characterization of mechanisms involved in presynaptic inhibition of sympathetic pressor effects induced by some 5-HT1 receptor antagonists. J Auton Pharmacol 20:313-323
10. Finer N (2001) Sibutramine in clinical practice. Int J Obes 25(Suppl 4): S12-S15
11. Finer N (2002) Sibutramine: its mode of action and efficacy. Int J Obes 26 (Suppl 4):S29-S33
12. Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR (1994) Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 18:129-135
13. Grubb BP, Samoil D, Kosinski D, Wolfe D, Lorton M, Madu E (1994) Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am J Med 97:366-368
14. Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M (2002) Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes 26:262-273
15. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P (1998) Efficacy and tolerability of sibutramine in obese patients: a dose ranging study. Int J Obes 22:32-38
16. Hansen DL, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, Rössner S, Saris WHM, Van Gaal LF, James WPT, Goulder M (2001) Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trail. Int J Obes 25:496-501
17. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A (1999) The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes 23:1016-1024
18. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K (2004) Weight reduction by sibutramine in obese subjects in primary care medicine: the S. A. T. study. Exp Clin Endocrinol Diabetes 112:201-207
19. Haynes WG, Mark AL (2002) Pharmacotherapy of obesity: lessons from clinical trials in hypertension. J Hypertens 20:1731-1735
20. Hazenberg G (2000) Randomized, double-blind, placebo-controlled multicenter study of sibutramine in obese hypertensive patients. Cardiol 94: 152-158
21. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WHM, Van Gaal LF (2000) Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 356:2119-2125
22. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM (2005) Influence of sibutramine on blood-pressure: evidence from placebo-controlled trials. Int J Obes 29:1-8
23. Krejs GJ (2002) Metabolic benefits associated with sibutramine therapy. Int J Obes 26(Suppl 4):S34-S37
24. Lean MEJ (2001) How does sibutramine work? Int J Obes 25(Suppl 4):S8-S11
25. Levine LR, Rosenblatt, Bosomworth J (1987) Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int J Obes 11(Suppl 3): S185-S190
26. McCall RB, Patel BN, Harris LT (1987) Effects of serotonin 1 and serotonin 2 receptor agonists and antagonists on blood pressure, heart rate and sympathetic nerve activity. J Pharmacol Exp Ther 242:1152-1159
27. McGuirk J, Silverstone T (1990) The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes 14:361-372
28. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD (2000) Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160:2185-2191
29. Moffitt JA, Johnson AK (2004) Short-term fluoxetine treatment enhances baroreflex control of sympathetic nervous system activity after hindlimb unloading. Am J Physiol Regul Integr Comp Physiol 286:R584-R590
30. Narkiewicz K (2002) Sibutramine and its cardiovascular profile. Int J Obes 26(Suppl 4):S38-S41
31. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM (2003) Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42:878-884
32. Samoil D, Grubb BP (1995) Neurally mediated syncope and serotonin reuptake inhibitors. Clin Auton Res 5:251-255
33. Sharma AM (2001) Sibutramine in overweight/obese hypertensive patients. Int J Obes 25(Suppl 4):S20-S23
34. Shores MM, Pascualy M, Lewis NL, Flatness D, Veith RC (2001) Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 26:433-439
35. Walsh KM, Leen E, Lean MEJ (1999) The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes 23:1009-1015
36. Wirth A, Krause J (2001) Long-term weight loss with sibutramine, a randomized controlled trial. JAMA 286: 1331-1339